The Global N,N’-Carbonyldiimidazole (CDI) Market was valued at USD 48.7 Million in 2024 and is projected to reach USD 75.8 Million by 2032, growing at a Compound Annual Growth Rate (CAGR) of 5.4% during the forecast period (2024–2032). This growth is being driven by expanding pharmaceutical R&D activities, rising demand for agrochemical intermediates, and the accelerating adoption of green chemistry practices across pharmaceutical and specialty chemical manufacturing sectors.

As the specialty chemicals industry transforms toward cleaner synthesis methodologies and sustainable production, the spotlight is on the key CDI producers who are driving innovation, efficiency, and higher-purity reagent solutions. In this blog, we profile the Top 10 Companies in the N,N’-Carbonyldiimidazole (CDI) Industry—a mix of multinational chemical manufacturers, specialized regional producers, and API-focused innovators shaping the future of global CDI supply.

---

🔺 1. Lanxess AG

Headquarters: Cologne, Germany
Key Offering: High-Purity CDI (98% and 99% grades), Pharmaceutical-Grade Coupling Agents

Lanxess AG stands as one of the most dominant players in the global CDI market, leveraging its well-established chemical production infrastructure and deep-rooted partnerships with pharmaceutical companies across Europe and North America. The company supplies CDI primarily for peptide synthesis and active pharmaceutical ingredient (API) manufacturing, where consistent purity and regulatory compliance are non-negotiable requirements.

Key Strengths:

• Established supply relationships with major pharmaceutical manufacturers in Europe and North America

• Strong compliance with REACH and FDA chemical safety standards

• Ongoing R&D into high-purity CDI synthesis for advanced therapeutic applications

Download FREE Sample Report:
N,N’-Carbonyldiimidazole (CDI) Market – View in Detailed Research Report

---

� 2. Atul Limited

Headquarters: Valsad, Gujarat, India
Key Offering: CDI for Pharmaceutical Intermediates and Agrochemical Applications

Atul Limited is India’s leading CDI producer and one of the most competitive suppliers in the Asia-Pacific region. The company has built a strong reputation for delivering cost-effective CDI solutions without compromising on quality, making it particularly attractive to generic drug manufacturers and agrochemical producers operating in price-sensitive markets.

Key Strengths:

• Integrated chemical manufacturing capabilities that reduce input costs

• Growing export footprint to regulated pharmaceutical markets in the US and Europe

• Active capacity expansions to meet rising domestic and international CDI demand

---

� 3. Zhejiang Bulk Chemical Co., Ltd.

Headquarters: Zhejiang Province, China
Key Offering: CDI (Purity 98% and 99%), Bulk Pharmaceutical Chemical Intermediates

Zhejiang Bulk Chemical has emerged as a formidable force in the Chinese CDI market, capitalizing on the country’s extensive chemical manufacturing infrastructure. The company produces CDI at scale, serving both domestic pharmaceutical producers and international buyers looking for competitively priced reagents. Its position in China gives it direct access to one of the world’s fastest-growing API manufacturing ecosystems.

Key Strengths:

• High-volume production capability supporting cost-competitive pricing strategies

• Approximately 28% share of regional CDI production capacity in Asia-Pacific alongside Atul Limited

• Broad client base spanning pharmaceutical manufacturers, research laboratories, and contract manufacturing organizations

---

� 4. Hangzhou FST Pharmaceutical Co., Ltd.

Headquarters: Hangzhou, Zhejiang, China
Key Offering: High-Purity CDI (99% grade), Peptide Synthesis Reagents

Hangzhou FST Pharmaceutical has carved a distinctive niche by focusing specifically on high-purity CDI formulations tailored for regulated pharmaceutical applications. The company’s investment in advanced synthesis techniques has enabled it to compete directly with established Western manufacturers in demanding markets that require reagents meeting stringent pharmacopeial standards.

Key Strengths:

• Specialization in 99% purity CDI for oncology and peptide therapeutics manufacturing

• Expanding technical capabilities in solid-phase peptide synthesis (SPPS) applications

• Growing international customer base in North America and European regulated markets

Download FREE Sample Report:
N,N’-Carbonyldiimidazole (CDI) Market – View in Detailed Research Report

---

� 5. Hangzhou Yunuo Chemical Co., Ltd.

Headquarters: Hangzhou, Zhejiang, China
Key Offering: CDI, Specialty Chemical Intermediates

Hangzhou Yunuo Chemical is a well-established Chinese producer of CDI and related specialty intermediates, serving a diverse customer base that spans pharmaceutical manufacturers, agrochemical producers, and contract research organizations. The company benefits from Hangzhou’s dense concentration of life sciences and chemical companies, which facilitates efficient supply chain integration.

Key Strengths:

• Broad product portfolio covering multiple CDI purity grades

• Strong regional distribution network within China’s pharmaceutical intermediate market

• Responsive technical support for custom synthesis requirements

---

� 6. Changzhou Welton Chemical Co., Ltd.

Headquarters: Changzhou, Jiangsu, China
Key Offering: CDI, Fine Chemical Reagents

Changzhou Welton Chemical represents the growing segment of mid-sized Chinese specialty chemical producers that are steadily upgrading their technical capabilities to compete in regulated pharmaceutical applications. The company has made notable investments in improving CDI synthesis purity and handling protocols, enabling it to serve customers who were previously restricted to higher-cost Western suppliers.

Key Strengths:

• Competitive pricing model that appeals to cost-conscious pharmaceutical and agrochemical manufacturers

• Increasing capability in producing pharmaceutical-grade CDI for international export

• Flexible batch production capability accommodating both small and large orders

---

� 7. Quzhou Ruilijie Chemical Industry Co., Ltd.

Headquarters: Quzhou, Zhejiang, China
Key Offering: CDI, Carbonylation Reagents

Quzhou Ruilijie Chemical Industry operates within one of China’s most active chemical manufacturing clusters and has developed a credible position in CDI production for domestic markets. The company primarily supplies manufacturers in the pesticide intermediate and general chemical synthesis segments, where CDI’s efficiency as a carbonylation and coupling agent is particularly valued.

Key Strengths:

• Strategic location within Zhejiang’s integrated chemical manufacturing ecosystem

• Focus on agrochemical and specialty polymer applications of CDI

• Competitive raw material sourcing advantages within regional supply chains

---

� 8. Jiangsu Zhenri Chemical Co., Ltd.

Headquarters: Jiangsu Province, China
Key Offering: CDI, Pharmaceutical Chemical Intermediates

Jiangsu Zhenri Chemical has built a steady presence in the CDI market by focusing on reliable supply and quality consistency for domestic pharmaceutical intermediate manufacturers. Jiangsu Province is home to a significant concentration of China’s pharmaceutical production capacity, which gives Jiangsu Zhenri natural access to a large and growing customer base that values local supply security.

Key Strengths:

• Proximity to major API manufacturing hubs in Jiangsu Province

• Emphasis on supply consistency and on-time delivery for pharmaceutical customers

• Expanding production capacity to meet growing regional demand for pharmaceutical intermediates

Download FREE Sample Report:
N,N’-Carbonyldiimidazole (CDI) Market – View in Detailed Research Report

---

� 9. Shanghai Holdenchem Co., Ltd.

Headquarters: Shanghai, China
Key Offering: CDI, Specialty Chemical Trading and Distribution

Shanghai Holdenchem has distinguished itself through a strategic combination of CDI manufacturing and distribution expertise, making it an important node in China’s specialty chemical supply chain. The company’s 2023 acquisition of Linhai Kaile Chemical Factory significantly expanded its production footprint and distribution capabilities, particularly within China’s active pharmaceutical ingredient sector. This move reflects the broader consolidation trend reshaping the competitive landscape.

Key Strengths:

• Expanded production capacity following strategic acquisition of Linhai Kaile Chemical Factory

• Strong distribution network connecting CDI supply with downstream API manufacturers across China

• Growing capability in serving both domestic and export pharmaceutical markets

---

� 10. TCI Chemicals (Tokyo Chemical Industry Co., Ltd.)

Headquarters: Tokyo, Japan
Key Offering: Research-Grade and High-Purity CDI, Fine Chemical Reagents

TCI Chemicals is a globally recognized supplier of fine chemicals and research reagents, and its CDI offering is well-established among pharmaceutical research institutions, contract research organizations, and academic laboratories worldwide. While TCI operates primarily in the research and development segment rather than large-scale industrial production, it plays an important role in driving CDI adoption in early-stage drug discovery and new application development.

Key Strengths:

• Global reach with distribution centers serving research markets in Asia, Europe, and North America

• Stringent quality control ensuring high-purity CDI for sensitive research applications

• Broad catalog of complementary peptide synthesis and coupling reagents supporting CDI users

Get Full Report Here:
N,N’-Carbonyldiimidazole (CDI) Market – View in Detailed Research Report

---

🌎 Outlook: The Future of the CDI Market Is Greener and More Innovation-Driven

The N,N’-Carbonyldiimidazole market is undergoing a meaningful transformation. While pharmaceutical synthesis continues to dominate consumption, the industry is investing in specialty formulation development, green chemistry integration, and expanded agrochemical applications that will broaden CDI’s relevance across multiple end-use sectors through 2032 and beyond.

📈 Key Trends Shaping the Market:

• Rapid expansion of API manufacturing capacity in China and India driving sustained CDI demand growth

• Regulatory pressure toward green synthesis practices increasing CDI adoption as a clean coupling agent

• Development of ultra-high purity CDI formulations (≥99.5%) for advanced oncology and biologics applications

• Growing agrochemical sector diversifying CDI consumption beyond its traditional pharmaceutical base

• Strategic mergers and acquisitions consolidating production capacity among Chinese specialty chemical producers

Get Full Report Here:
N,N’-Carbonyldiimidazole (CDI) Market – View in Detailed Research Report

The companies profiled above are not only supplying a critical reagent to global pharmaceutical and chemical industries—they’re spearheading the next generation of cleaner, more efficient synthesis that will define specialty chemical manufacturing for decades to come.